Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Tofacitinib might be used to treat hair loss.

The patient was satisfied with hormone therapy, and her epilepsy remained stable.

An arthritis drug helped a person with severe hair loss regrow their hair.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

Ayurvedic treatments may help reduce hypothyroidism symptoms.

HIF-1A may aid hair growth, Backhousia citriodora improves skin, autologous cells stabilize hair loss, infrared thermography assesses alopecia, and a new treatment preserves hair.

Scientists turned rat thymus cells into stem cells that can help repair skin and hair.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Enhancing Tregs can protect against alopecia areata.

Pulsed electric field treatment may help shrink untreated liver tumors.

Skin changes can help predict thyroid diseases.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

ATP-sensitive potassium channels are important for hair growth.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

New skin treatments in 1987-1988 showed effectiveness for various conditions, but some had side effects or risks.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.